San Ne Paartanar Mark Ki Blockbuster Dava Ko Kiya Chaileinj

Business »

San Ne Paartanar Mark Ki Blockbuster Dava Ko Kiya Chaileinj

soma das nai Delhi Indian dava company san pharma ko ameriki dava reguletar se pichhle hafte jenuviya ke jenerik varjan ke liye teintetiv aprooval mila hai. Isse enaalists ke beech yah bahas tej ho gayi hai ki company ne is blockbuster anti-daayabiteej drag ke peteint ko chunauti day di hai. Yah faisala hairaan karne vaala hai. Iski vajah yah hai ki san ne ameriki malteeneshanal farm emaesadi ke saath domestik market ke liye gathajod kiya tha, taaki isi dava ke liye glenamaark ke peteint ullanghan maamale mein mukadama kiya ja sake. Yooes food end drag edaministreshan (yooesaefadeee) se teintetiv aprooval milne ki khabar ki pushti karte hue san pharma ke pravakta ne bataaya ki vah faailing ke nechar ke baare mein koi tippani naheen kareinge. San pharma 2022 mein hi iska jenerik varjan launch kar paaegi. Industry ke jaankaaron ka kehna hai ki dava ke peteint ke eksapaayar hone ke 12-14 saal pehle daakhil ki gayi arji shaayad paira-4 eplikeshan ho sakti hai. Iska matlab hai ki san pharma ne ya to emaesadi ke jenuviya ki vailiditi ko chunauti hai ya yah maana hai ki iska jenerik varjan emaesadi ke peteint ka ullanghan naheen karega. Jenuviya ke besik kanpaaund se sambandhit peteint America mein 2022 mein eksapaayar hoga, jabki sault ya product (beche jaane vaale monofosfet varjan) 2026 mein eksapaayar hoga. Naam na jaahir karne ki shart par ek enaalist ne kaha, 'Agar aap vah taareekh dekhein, jis din san pharma ne sault jenuviya ke liye ebriviyeted drag eplikeshan file ki thi, to yah 18 October 2010 hai. Yah enaseei-1 ke do din baad ki taareekh hai. Enaseei-1 paira 4 eplikeshan file karne ki aakhiri taareekh hai. ' ameriki jenerik company maayalaan aur Swiss dava company novaartis ki jenerik ikaai saindoj ne bhi isi dauraan apni eplikeshans file ki theen. San pharma ki jenuviya par India straiteji 2011 mein majaboot hui. Tab company ne emaesadi ke saath jenuviya samet anya daayabiteej prodakts ke maarketing, promotion aur distribyooshan ke liye emaesadi ke saath haath milaaya tha. Emaesadi ke pravakta ne kaha, 'Ham san pharma ke saath America mein sitaigliptin (jenuviya ka jenerik naam) ke liye kisi kaanooni vivaad mein naheen hain. Yooesaefadeee se teintetiv aprooval milna ya iske liye faailing jenerik product ko bechne ka adhikaar naheen deta hai. Ise 2022 mein jab peteint eksapaayar hoga, tab tak launch naheen kiya ja sakta hai. Humne san ke khilaaf koi kaanooni kadam naheen uthaaya hai. '

San Ne Paartanar Mark Ki Blockbuster Dava Ko Kiya Chaileinj https://www.angrejinews.com/pic/5676